CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...